InVivo Therapeutics Holdings Corp (NVIVQ)

[DDobserver]

Sixty percentage of enrollment over a two year period. Another two years for the additional patients to be enrolled and reviewed. Then a year or longer for review and potential approval assuming nothing is unexpected. Minimal communication from management and executives. Insider trades non existent. Conclusion dead money for an additional three years minimum.

I challenge management to give us guidance considering the retail stockholder does not buy in at a price as low as .29 p/s. Management owes the ownership that much at a bare minimum and can do so without breaking any laws or confidentiality agreements. It appears they prefer to say little to nothing and expect people to guess while choosing not to communicate on the most simplistic level. Sad, misguided,and/or trying to pull the wool over eyes...I have not decided. What I have decided is they are compensated well for their individual skill sets.